Flaharty Asset Management’s BioAtla BCAB Stock Holding History

Flaharty Asset Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-83	Closed	-$1.44K	–	164
2025 Q1	$1.44K	Buy	+83	New	+$1.77K	﹤0.01%	463

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Flaharty Asset Management's BCAB Position: Q2 2025 in Review

Flaharty Asset Management sold out of BioAtla (BCAB) in Q2 2025, closing a stake of 83 shares — an estimated $1.44K sold.

Flaharty Asset Management first reported a position in BCAB in Q1 2025 and held it in 1 quarter. The position peaked at $1.44K in Q1 2025. 39 funds tracked by Wall St. Rank hold BCAB as of Q2 2025.

Flaharty Asset Management reported no remaining BioAtla position as of Q2 2025 after selling out during the quarter.
Flaharty Asset Management sold 83 BioAtla shares in Q2 2025, an estimated $1.44K.
Flaharty Asset Management first reported a position in BioAtla in Q1 2025 and held it in 1 quarter.
Flaharty Asset Management's BioAtla position peaked at $1.44K in Q1 2025.
39 funds tracked by Wall St. Rank held BioAtla as of Q2 2025.

Based on Flaharty Asset Management's 13F filing for Q2 2025, filed 8 Aug 2025.